Evidence map›Paper›PMID 32435610›Full record

ArticleJournal of translational internal medicine2020

MiR-155 and MiR-665 Role as Potential Non-invasive Biomarkers for Hepatocellular Carcinoma in Egyptian Patients with Chronic Hepatitis C Virus Infection.

Amal Ahmed Mohamed, Abdellah Abosrie Ali Omar, Rehab R El-Awady, Sally Mohamed Aboelsayed Hassan, Waleed Mohamed Soliman Eitah, Rehab Ahmed, Amir Khater, Omnia Mohamed Saad Tantawi, Ahmed Abdelhafeez Mohamed

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational internal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 3 pooled it
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Amal Ahmed MohamedBiochemistry and Molecular Biology Department, National Hepatology and Tropical Medicine Research institute, Cairo, Egypt.
Abdellah Abosrie Ali OmarMedical Biochemistry Department, Faculty of Medicine (Boys), Al-Azhar University Cairo, Egypt.
Rehab R El-AwadyBiochemistry Department, Faculty of Pharmacy (Girls), AL-Azhar University Cairo, Egypt.
Sally Mohamed Aboelsayed HassanBiochemistry Department, Faculty of Pharmacy (Girls), AL-Azhar University Cairo, Egypt.
Waleed Mohamed Soliman EitahGastroenterology and Hepatology Department, Theodor Bilharz Research Institute, Cairo, Egypt.
Rehab AhmedTropical Department, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.
Amir KhaterTropical Department, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.
Omnia Mohamed Saad TantawiEndemic Diseases Department, Kasraliny, Cairo University, Cairo, Egypt.
Ahmed Abdelhafeez MohamedClinical Oncology Department, Kasralainy, Cairo University, Cairo, Egypt.
Al-Azhar University · EGNational Water Research Center · EGCairo University · EGTheodor Bilharz Research Institute · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesHepatocellular carcinoma (HCC) is the fourth leading cause of cancer associated death globally. Serum micro RNAs are full of potential as noninvasive biomarkers. Here, we aim to assess the performance of serum MicroRNA-155 and MicroRNA-665 as diagnostic biomarker for HCC comparing to AFP.

methodsSerum samples were collected from 200 subjects (40 healthy control, 80 chronic hepatitis C patients with cirrhosis and without HCC (LC) and 80 HCC patients currently infected by hepatitis C infection and didn't start the treatment). The HCC patients didn't include alcoholic liver disease, nonalcoholic fatty liver disease nor autoimmune liver disease. MicroRNA-155 and MicroRNA-665 expression were measured by real-time quantitative PCR (RT-qPCR), while AFP level was assessed by ELISA method.

resultsBoth miR-155 and miR-665 were significantly elevated in HCC group as compared to both control and LC groups. The comparison between LC and HCC patients revealed that the serum level of miR-155 was a significant increase in HCC patients compared to LC patients; however, the serum level of miR-665 didn't show any significant difference between the same two groups. MiR-665 expression level showed a direct correlation with tumor size in HCC patients.

conclusionsUsing measurement against AFP level in serum, miR-665 is considered a promising serum biomarker for the diagnosis of HCC patients among the LC patients without HCC. MiR-155 didn't provide a better performance than serum AFP as a diagnostic biomarker among the same group. MiR-665 may serve as a good indicator for HCC prognosis.

Indexed as

alpha-fetoprotein (AFP)chronic hepatitis with cirrhosis C and without HCC (LC)hepatocellular carcinoma (HCC)micro RNAs (miRNA)

Identifiers

PMID32435610
PMCPMC7227164
OpenAlexW3028134915

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.